SlideShare a Scribd company logo
David Barounis
             R-2
Advocate Christ Medical Center
Some Questions to the
Audience
1.   How much does FFP cost and how
     much do you need to give in reversal of
     coumadin associated life threatening
     bleed??
Some Questions to the
Audience
1.   How much does FFP cost and how
     much do you need to give in reversal of
     coumadin associated life threatening
     bleed??
     A: $1/ml, typically need 4U for reversal
     with 250cc/unit = $1000.

1.   What other products are available here
     at christ hospital for reversal of oral
     anticoagulants?
Case 1
1.   65y/o F with A-fib presents on Pradaxa
     presents with an ICH approximately
     25cc volume with no significant shift.

     What’s you next move??
Case 2
   58y/o M s/p total hip replacement on
    rivaroxaban for DVT prophylaxis
    presents with lightheadness and
    weakness. Hgb is 4.2 guaic negative
    from below.

   Where is the bleed?
Case 2
 58y/o M s/p total hip replacement on
  rivaroxaban for DVT prophylaxis
  presents with lightheadness and
  weakness. Hgb is 4.2 guaic negative
  from below.
 Where is the bleed?


   CT A/P: Large retroperitoneal hematoma
Coagulation Cascade
Coagulation Cascade
The ER coagulation
cascade
                                    Tissue Damage
  OTHER FACTORS
  V, VIII, IX, XI, XII

                                    1.FACTOR VIIa



                             2.FACTOR Xa ==FACTOR X



                  3.PROTHROMBIN== THROMBIN



                           FIBRONGEN ==FIBRIN CLOTS
The ER coagulation
cascade
  COUMADIN

                                    Tissue Damage
  OTHER FACTORS
  V, VIII, IX, XI, XII

                                    1.FACTOR VIIa



                             2.FACTOR Xa ==FACTOR X



                  3.PROTHROMBIN== THROMBIN



                           FIBRONGEN ==FIBRIN CLOTS
The ER coagulation
cascade
                                      Tissue Damage
  OTHER FACTORS
  V, VIII, IX, XI, XII      LOVENOX

                                      1.FACTOR VIIa


                 AT III
 HEPARIN                     2.FACTOR Xa ==FACTOR X



                  3.PROTHROMBIN== THROMBIN



                           FIBRONGEN ==FIBRIN CLOTS
Dabigatran(Pradaxa)
   Direct Thrombin Inhibitor

   Approved for anti-coagulation in patients
    with non-valvular atrial fibrillation

   RE-LY trial comparing coumadin to
    Dabigatran
The ER coagulation
cascade
                                    Tissue Damage
  OTHER FACTORS
  V, VIII, IX, XI, XII

                                    1.FACTOR VIIa



                             2.FACTOR Xa ==FACTOR X



                  3.PROTHROMBIN== THROMBIN         PRADAXA


                           FIBRONGEN ==FIBRIN CLOTS
Back to Case 1
   ICB in patient on pradaxa

  Step 1: What is the patients aPTT?
The PTT, typically 1.5X normal 12hours
after last dose. If < 32 seconds unlikely for
patient to have high enough blood
concentrations for benefit from reversal
Novel Reversal Agents
1. PCC
WE DO NOT HAVE PCC’s here at Christ
Hospital.

Cost is similar to 4U of FFP($1000 vs $1200)
USA 3 factor PCC’s only (does not contain high quantity
of factor VII)

So assuming 4U (1L) of FFP vs 2000U of Profilnine
Factor II: 1000U FFP : 2900U Profilnine
Factor IX: 1000U FFP : 2000U Profilnine
Factor VII: 1000U FFP: 700U Profilnine
Factor X: 1000U FFP : 1200U Profilnine
PCC’s Safety




*1.4% complication rate (3 CVA, 2 DVT, and 2 non Q wave MI’s)
The ER coagulation
cascade
                                    Tissue Damage
  OTHER FACTORS
  V, VIII, IX, XI, XII

                                    1.FACTOR VIIa



 PCC’s                       2.FACTOR Xa ==FACTOR X



                  3.PROTHROMBIN== THROMBIN         PRADAXA


                           FIBRONGEN ==FIBRIN CLOTS
Are they effective in patients
with non-VKA?
Reversal of Rivaroxaban and Dabigatran by Prothrombin
Complex Concentrate. Circulation 2011


12 healthy volunteers: No effect of PCC on Dabigatran
reversal, completely reversed measured anticoagulation in
subjects receiving Rivaroxaban.

JUST REMEMBER THIS IS IN HEALTHY PT VOLUNTEERS
WITHOUT HEAD BLEEDS!!!
Activated Factor VIIa
(Novo7)
   Recommended by the makers of Dabigatran as
    the “Reversal agent of choice”.

   Dose 90mcg/kg = 1mg

   Very short half life and often requires repeated
    dosing ($1.13/mcg, usually need 1mg X 4 INITIAL
    X 4 MAINTENCE OVER 4-6 HOURS= $55,000)
Safety of Novo7
   Thromboembolic Adverse Events (TAE)

249/3184 = 7.8% (placebo 6.2% RR 1.37)

*Arterial TAE OR 1.5 (95%CI 0.93-2.41)

Venous TAE OR 0.76 (95% CI 0.49-1.15)

*Trend toward statistical significance (>5%
incidence in the elderly > 65.)
Efficacy for reversal in ICH
Hemostatic Drug Therapies for Acute Spontaneous
Intracerebral Hemorrhage. Cochrane Database of
System Rev 2009.

Death 18.5% (rFVIIa) vs 19.4% (Placebo) RR 0.85
Death and/or Dependence 49.6% vs 51.7% RR 0.91

Essentially ineffective when looking at outcomes like
Mortality, which is all that really matters.
The ER coagulation
cascade
                                    Tissue Damage
  OTHER FACTORS
  V, VIII, IX, XI, XII

                                    1.FACTOR VIIa       NOVO 7



                             2.FACTOR Xa ==FACTOR X



                  3.PROTHROMBIN== THROMBIN         PRADAXA


                           FIBRONGEN ==FIBRIN CLOTS
FEIBA
   Activated Prothrombin Complex
    Concentrates (II, VII, IX, and X)

   Dose 500U -1000U Often repeated for
    sustained effect up to 2000Units

 Cost $1.59U/1000U = $1600/dose
 Typically 1-3 doses given
Safety
Cezary et al. Activated prothrombin complex concentrate
factor VIII inhibitor bypassing activity (FEIBA) for the
reversal of warfarin-induced coagulopathy. Int J Emerg
Med 2009.


Complications:
4/72 or 7% (1 peri-operative MI, 1 thrombosis of
CVC, 2 NSTEMI) VERY conservative.
FEIBA Efficacy
FEIBA used in warfarin reversal:

72 patients with life-threatening bleeds on coumadin.
54% Had INR < 1.4, vs 30% of patients who received
FFP.

No mortality benefit, reduced hematoma expansion
after ICH, rapid reversal of INR immediately (<15
minutes)
The ER coagulation
cascade
                                    Tissue Damage
  OTHER FACTORS
  V, VIII, IX, XI, XII

                                    1.FACTOR VIIa


   FEIBA
                             2.FACTOR Xa ==FACTOR X



                  3.PROTHROMBIN== THROMBIN         PRADAXA


                           FIBRONGEN ==FIBRIN CLOTS
Recommendations
   Evidence is poor

   Really endpoints like mortality are lacking

   No good RCT comparing these options
    exist.

   Head bleeds are bad, GI bleeds are better,
    and maybe reversing people doesn’t do
    anything at all.
In light of good evidence
1.   Pradaxa: check aPTT, if < 1.5normal = DONE
-    FEIBA 500U
-    rFVIIa 90mch/kg X 1 or about 1mg
-    FFP and HEMODIALYSIS (if you can find someone to dialyze them)
-    Activated Charcoal if within 2 hours of ingestion

2.   Rivoroxaban:
-    PCC’s 50U/kg Profilnine
-    FEIBA 500-1000U

3.   Warfarin
-    FFP 15-20cc/kg minimum of 4U
-    PCC’s > FFP for time to reversal (cost is similar)
-    We have FEIBA (cost is more but rapidly reduces reversal time)
THANKS!!!

More Related Content

Viewers also liked

Rivaroxaban
RivaroxabanRivaroxaban
Rivaroxaban
tgraphos
 
Newer anticoagulants
Newer anticoagulantsNewer anticoagulants
Newer anticoagulants
aravazhi
 
Anti platelet agents
Anti platelet agentsAnti platelet agents
Anti platelet agents
Doc Pradeep
 
new oral anticoagulants
new oral anticoagulantsnew oral anticoagulants
new oral anticoagulants
derosaMSKCC
 

Viewers also liked (20)

25.anticoagulants
25.anticoagulants  25.anticoagulants
25.anticoagulants
 
Oral-Anti coagulants
Oral-Anti coagulantsOral-Anti coagulants
Oral-Anti coagulants
 
Xarelto
Xarelto Xarelto
Xarelto
 
What you need to know about Xarelto
What you need to know about XareltoWhat you need to know about Xarelto
What you need to know about Xarelto
 
Rivaroxaban
RivaroxabanRivaroxaban
Rivaroxaban
 
Dabigatrán + idarucizumab
Dabigatrán + idarucizumab Dabigatrán + idarucizumab
Dabigatrán + idarucizumab
 
Newer oral anticoagulant 8.9.16
Newer oral anticoagulant 8.9.16Newer oral anticoagulant 8.9.16
Newer oral anticoagulant 8.9.16
 
Dabigatran
DabigatranDabigatran
Dabigatran
 
New New Oral Anticoagulants 2014
New New Oral Anticoagulants 2014New New Oral Anticoagulants 2014
New New Oral Anticoagulants 2014
 
Newer anticoagulants
Newer anticoagulantsNewer anticoagulants
Newer anticoagulants
 
Antidote for NOACs
Antidote for NOACsAntidote for NOACs
Antidote for NOACs
 
Anticoagulation Pharmacology
Anticoagulation PharmacologyAnticoagulation Pharmacology
Anticoagulation Pharmacology
 
Antiplatelet Therapy: What’s New, Older Agents and How They Work
Antiplatelet Therapy: What’s New, Older Agents and How They WorkAntiplatelet Therapy: What’s New, Older Agents and How They Work
Antiplatelet Therapy: What’s New, Older Agents and How They Work
 
New Oral Anticoagulants
New Oral AnticoagulantsNew Oral Anticoagulants
New Oral Anticoagulants
 
Heparin
HeparinHeparin
Heparin
 
Newer anti-platelets final.
Newer anti-platelets final.Newer anti-platelets final.
Newer anti-platelets final.
 
Anti platelet agents
Anti platelet agentsAnti platelet agents
Anti platelet agents
 
Bioassay of Heparin
Bioassay of HeparinBioassay of Heparin
Bioassay of Heparin
 
new oral anticoagulants
new oral anticoagulantsnew oral anticoagulants
new oral anticoagulants
 
Noacs
NoacsNoacs
Noacs
 

Similar to Emergent reversal

Dr. neeraj-presentation-23-des
Dr. neeraj-presentation-23-desDr. neeraj-presentation-23-des
Dr. neeraj-presentation-23-des
DrNeerajB
 
Dr. neeraj-presentation-23-des
Dr. neeraj-presentation-23-desDr. neeraj-presentation-23-des
Dr. neeraj-presentation-23-des
DrNeerajB
 
Anticoagulants naser
Anticoagulants naserAnticoagulants naser
Anticoagulants naser
Naser Tadvi
 
Trauma induced coagulopathy
Trauma induced coagulopathyTrauma induced coagulopathy
Trauma induced coagulopathy
Abdulgafoor MT
 
Anticoagulation and haemostasis during cardiopulmonary bypass
Anticoagulation and haemostasis during cardiopulmonary bypassAnticoagulation and haemostasis during cardiopulmonary bypass
Anticoagulation and haemostasis during cardiopulmonary bypass
Dhritiman Chakrabarti
 
Thrombolytics and Antithrombolytics.pptx
Thrombolytics and Antithrombolytics.pptxThrombolytics and Antithrombolytics.pptx
Thrombolytics and Antithrombolytics.pptx
Mangaiarkkarasi
 
高亮:Traumatic Brain Injury Associated Coagulopathy
高亮:Traumatic Brain Injury Associated Coagulopathy高亮:Traumatic Brain Injury Associated Coagulopathy
高亮:Traumatic Brain Injury Associated Coagulopathy
neuroccm
 
Woods Anticoag Antianem 09
Woods Anticoag Antianem 09Woods Anticoag Antianem 09
Woods Anticoag Antianem 09
pharmdude
 

Similar to Emergent reversal (20)

Drugs used in disorders of coagulation
Drugs used in disorders of coagulationDrugs used in disorders of coagulation
Drugs used in disorders of coagulation
 
Hemostasis
HemostasisHemostasis
Hemostasis
 
Dr. neeraj-presentation-23-des
Dr. neeraj-presentation-23-desDr. neeraj-presentation-23-des
Dr. neeraj-presentation-23-des
 
Dr. neeraj-presentation-23-des
Dr. neeraj-presentation-23-desDr. neeraj-presentation-23-des
Dr. neeraj-presentation-23-des
 
Anticoagulation in neurosurgery heparin warfarin_ppt
Anticoagulation in neurosurgery heparin warfarin_pptAnticoagulation in neurosurgery heparin warfarin_ppt
Anticoagulation in neurosurgery heparin warfarin_ppt
 
Anticoagulants naser
Anticoagulants naserAnticoagulants naser
Anticoagulants naser
 
Anticoagulant
AnticoagulantAnticoagulant
Anticoagulant
 
Trauma induced coagulopathy
Trauma induced coagulopathyTrauma induced coagulopathy
Trauma induced coagulopathy
 
Anticoagulants
AnticoagulantsAnticoagulants
Anticoagulants
 
Anticoagulation and haemostasis during cardiopulmonary bypass
Anticoagulation and haemostasis during cardiopulmonary bypassAnticoagulation and haemostasis during cardiopulmonary bypass
Anticoagulation and haemostasis during cardiopulmonary bypass
 
Thrombolytics and Antithrombolytics.pptx
Thrombolytics and Antithrombolytics.pptxThrombolytics and Antithrombolytics.pptx
Thrombolytics and Antithrombolytics.pptx
 
Oral anticoagulants ppt
Oral anticoagulants ppt Oral anticoagulants ppt
Oral anticoagulants ppt
 
Thrombophilia.ppt
Thrombophilia.pptThrombophilia.ppt
Thrombophilia.ppt
 
高亮:Traumatic Brain Injury Associated Coagulopathy
高亮:Traumatic Brain Injury Associated Coagulopathy高亮:Traumatic Brain Injury Associated Coagulopathy
高亮:Traumatic Brain Injury Associated Coagulopathy
 
Acquired hemophilia a
Acquired hemophilia aAcquired hemophilia a
Acquired hemophilia a
 
Emergency warfarin reversal a
Emergency warfarin reversal aEmergency warfarin reversal a
Emergency warfarin reversal a
 
Aniticoagulants
AniticoagulantsAniticoagulants
Aniticoagulants
 
Coagulants and anti coagulants
Coagulants and anti coagulantsCoagulants and anti coagulants
Coagulants and anti coagulants
 
Woods Anticoag Antianem 09
Woods Anticoag Antianem 09Woods Anticoag Antianem 09
Woods Anticoag Antianem 09
 
Oral anticoagulant
Oral anticoagulant Oral anticoagulant
Oral anticoagulant
 

More from ACMC EM Residency

More from ACMC EM Residency (6)

Shoulder radiography
Shoulder radiographyShoulder radiography
Shoulder radiography
 
Life after residency first day
Life after residency first dayLife after residency first day
Life after residency first day
 
Lar lecture series timeline
Lar lecture series timelineLar lecture series timeline
Lar lecture series timeline
 
Ortho jeopardy
Ortho jeopardyOrtho jeopardy
Ortho jeopardy
 
Childbirth emergencies (2)
Childbirth emergencies (2)Childbirth emergencies (2)
Childbirth emergencies (2)
 
Getting most out of Residency
Getting most out of ResidencyGetting most out of Residency
Getting most out of Residency
 

Recently uploaded

anas about venice for grade 6f about venice
anas about venice for grade 6f about veniceanas about venice for grade 6f about venice
anas about venice for grade 6f about venice
anasabutalha2013
 
Sustainability: Balancing the Environment, Equity & Economy
Sustainability: Balancing the Environment, Equity & EconomySustainability: Balancing the Environment, Equity & Economy
Sustainability: Balancing the Environment, Equity & Economy
Operational Excellence Consulting
 
chapter 10 - excise tax of transfer and business taxation
chapter 10 - excise tax of transfer and business taxationchapter 10 - excise tax of transfer and business taxation
chapter 10 - excise tax of transfer and business taxation
AUDIJEAngelo
 
FINAL PRESENTATION.pptx12143241324134134
FINAL PRESENTATION.pptx12143241324134134FINAL PRESENTATION.pptx12143241324134134
FINAL PRESENTATION.pptx12143241324134134
LR1709MUSIC
 

Recently uploaded (20)

anas about venice for grade 6f about venice
anas about venice for grade 6f about veniceanas about venice for grade 6f about venice
anas about venice for grade 6f about venice
 
Transforming Max Life Insurance with PMaps Job-Fit Assessments- Case Study
Transforming Max Life Insurance with PMaps Job-Fit Assessments- Case StudyTransforming Max Life Insurance with PMaps Job-Fit Assessments- Case Study
Transforming Max Life Insurance with PMaps Job-Fit Assessments- Case Study
 
Unveiling the Secrets How Does Generative AI Work.pdf
Unveiling the Secrets How Does Generative AI Work.pdfUnveiling the Secrets How Does Generative AI Work.pdf
Unveiling the Secrets How Does Generative AI Work.pdf
 
April 2024 Nostalgia Products Newsletter
April 2024 Nostalgia Products NewsletterApril 2024 Nostalgia Products Newsletter
April 2024 Nostalgia Products Newsletter
 
Skye Residences | Extended Stay Residences Near Toronto Airport
Skye Residences | Extended Stay Residences Near Toronto AirportSkye Residences | Extended Stay Residences Near Toronto Airport
Skye Residences | Extended Stay Residences Near Toronto Airport
 
Business Valuation Principles for Entrepreneurs
Business Valuation Principles for EntrepreneursBusiness Valuation Principles for Entrepreneurs
Business Valuation Principles for Entrepreneurs
 
G-Mica Wood Chip Particle board Table Design
G-Mica Wood Chip Particle board Table DesignG-Mica Wood Chip Particle board Table Design
G-Mica Wood Chip Particle board Table Design
 
Lookback Analysis
Lookback AnalysisLookback Analysis
Lookback Analysis
 
Sustainability: Balancing the Environment, Equity & Economy
Sustainability: Balancing the Environment, Equity & EconomySustainability: Balancing the Environment, Equity & Economy
Sustainability: Balancing the Environment, Equity & Economy
 
chapter 10 - excise tax of transfer and business taxation
chapter 10 - excise tax of transfer and business taxationchapter 10 - excise tax of transfer and business taxation
chapter 10 - excise tax of transfer and business taxation
 
What are the main advantages of using HR recruiter services.pdf
What are the main advantages of using HR recruiter services.pdfWhat are the main advantages of using HR recruiter services.pdf
What are the main advantages of using HR recruiter services.pdf
 
Accpac to QuickBooks Conversion Navigating the Transition with Online Account...
Accpac to QuickBooks Conversion Navigating the Transition with Online Account...Accpac to QuickBooks Conversion Navigating the Transition with Online Account...
Accpac to QuickBooks Conversion Navigating the Transition with Online Account...
 
RMD24 | Retail media: hoe zet je dit in als je geen AH of Unilever bent? Heid...
RMD24 | Retail media: hoe zet je dit in als je geen AH of Unilever bent? Heid...RMD24 | Retail media: hoe zet je dit in als je geen AH of Unilever bent? Heid...
RMD24 | Retail media: hoe zet je dit in als je geen AH of Unilever bent? Heid...
 
Affordable Stationery Printing Services in Jaipur | Navpack n Print
Affordable Stationery Printing Services in Jaipur | Navpack n PrintAffordable Stationery Printing Services in Jaipur | Navpack n Print
Affordable Stationery Printing Services in Jaipur | Navpack n Print
 
RMD24 | Debunking the non-endemic revenue myth Marvin Vacquier Droop | First ...
RMD24 | Debunking the non-endemic revenue myth Marvin Vacquier Droop | First ...RMD24 | Debunking the non-endemic revenue myth Marvin Vacquier Droop | First ...
RMD24 | Debunking the non-endemic revenue myth Marvin Vacquier Droop | First ...
 
Digital Transformation in PLM - WHAT and HOW - for distribution.pdf
Digital Transformation in PLM - WHAT and HOW - for distribution.pdfDigital Transformation in PLM - WHAT and HOW - for distribution.pdf
Digital Transformation in PLM - WHAT and HOW - for distribution.pdf
 
Cracking the Workplace Discipline Code Main.pptx
Cracking the Workplace Discipline Code Main.pptxCracking the Workplace Discipline Code Main.pptx
Cracking the Workplace Discipline Code Main.pptx
 
FINAL PRESENTATION.pptx12143241324134134
FINAL PRESENTATION.pptx12143241324134134FINAL PRESENTATION.pptx12143241324134134
FINAL PRESENTATION.pptx12143241324134134
 
Putting the SPARK into Virtual Training.pptx
Putting the SPARK into Virtual Training.pptxPutting the SPARK into Virtual Training.pptx
Putting the SPARK into Virtual Training.pptx
 
sales plan presentation by mckinsey alum
sales plan presentation by mckinsey alumsales plan presentation by mckinsey alum
sales plan presentation by mckinsey alum
 

Emergent reversal

  • 1. David Barounis R-2 Advocate Christ Medical Center
  • 2. Some Questions to the Audience 1. How much does FFP cost and how much do you need to give in reversal of coumadin associated life threatening bleed??
  • 3. Some Questions to the Audience 1. How much does FFP cost and how much do you need to give in reversal of coumadin associated life threatening bleed?? A: $1/ml, typically need 4U for reversal with 250cc/unit = $1000. 1. What other products are available here at christ hospital for reversal of oral anticoagulants?
  • 4. Case 1 1. 65y/o F with A-fib presents on Pradaxa presents with an ICH approximately 25cc volume with no significant shift. What’s you next move??
  • 5. Case 2  58y/o M s/p total hip replacement on rivaroxaban for DVT prophylaxis presents with lightheadness and weakness. Hgb is 4.2 guaic negative from below.  Where is the bleed?
  • 6. Case 2  58y/o M s/p total hip replacement on rivaroxaban for DVT prophylaxis presents with lightheadness and weakness. Hgb is 4.2 guaic negative from below.  Where is the bleed?  CT A/P: Large retroperitoneal hematoma
  • 9. The ER coagulation cascade Tissue Damage OTHER FACTORS V, VIII, IX, XI, XII 1.FACTOR VIIa 2.FACTOR Xa ==FACTOR X 3.PROTHROMBIN== THROMBIN FIBRONGEN ==FIBRIN CLOTS
  • 10. The ER coagulation cascade COUMADIN Tissue Damage OTHER FACTORS V, VIII, IX, XI, XII 1.FACTOR VIIa 2.FACTOR Xa ==FACTOR X 3.PROTHROMBIN== THROMBIN FIBRONGEN ==FIBRIN CLOTS
  • 11. The ER coagulation cascade Tissue Damage OTHER FACTORS V, VIII, IX, XI, XII LOVENOX 1.FACTOR VIIa AT III HEPARIN 2.FACTOR Xa ==FACTOR X 3.PROTHROMBIN== THROMBIN FIBRONGEN ==FIBRIN CLOTS
  • 12. Dabigatran(Pradaxa)  Direct Thrombin Inhibitor  Approved for anti-coagulation in patients with non-valvular atrial fibrillation  RE-LY trial comparing coumadin to Dabigatran
  • 13. The ER coagulation cascade Tissue Damage OTHER FACTORS V, VIII, IX, XI, XII 1.FACTOR VIIa 2.FACTOR Xa ==FACTOR X 3.PROTHROMBIN== THROMBIN PRADAXA FIBRONGEN ==FIBRIN CLOTS
  • 14. Back to Case 1  ICB in patient on pradaxa  Step 1: What is the patients aPTT? The PTT, typically 1.5X normal 12hours after last dose. If < 32 seconds unlikely for patient to have high enough blood concentrations for benefit from reversal
  • 15. Novel Reversal Agents 1. PCC WE DO NOT HAVE PCC’s here at Christ Hospital. Cost is similar to 4U of FFP($1000 vs $1200) USA 3 factor PCC’s only (does not contain high quantity of factor VII) So assuming 4U (1L) of FFP vs 2000U of Profilnine Factor II: 1000U FFP : 2900U Profilnine Factor IX: 1000U FFP : 2000U Profilnine Factor VII: 1000U FFP: 700U Profilnine Factor X: 1000U FFP : 1200U Profilnine
  • 16. PCC’s Safety *1.4% complication rate (3 CVA, 2 DVT, and 2 non Q wave MI’s)
  • 17. The ER coagulation cascade Tissue Damage OTHER FACTORS V, VIII, IX, XI, XII 1.FACTOR VIIa PCC’s 2.FACTOR Xa ==FACTOR X 3.PROTHROMBIN== THROMBIN PRADAXA FIBRONGEN ==FIBRIN CLOTS
  • 18. Are they effective in patients with non-VKA? Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate. Circulation 2011 12 healthy volunteers: No effect of PCC on Dabigatran reversal, completely reversed measured anticoagulation in subjects receiving Rivaroxaban. JUST REMEMBER THIS IS IN HEALTHY PT VOLUNTEERS WITHOUT HEAD BLEEDS!!!
  • 19. Activated Factor VIIa (Novo7)  Recommended by the makers of Dabigatran as the “Reversal agent of choice”.  Dose 90mcg/kg = 1mg  Very short half life and often requires repeated dosing ($1.13/mcg, usually need 1mg X 4 INITIAL X 4 MAINTENCE OVER 4-6 HOURS= $55,000)
  • 20. Safety of Novo7  Thromboembolic Adverse Events (TAE) 249/3184 = 7.8% (placebo 6.2% RR 1.37) *Arterial TAE OR 1.5 (95%CI 0.93-2.41) Venous TAE OR 0.76 (95% CI 0.49-1.15) *Trend toward statistical significance (>5% incidence in the elderly > 65.)
  • 21. Efficacy for reversal in ICH Hemostatic Drug Therapies for Acute Spontaneous Intracerebral Hemorrhage. Cochrane Database of System Rev 2009. Death 18.5% (rFVIIa) vs 19.4% (Placebo) RR 0.85 Death and/or Dependence 49.6% vs 51.7% RR 0.91 Essentially ineffective when looking at outcomes like Mortality, which is all that really matters.
  • 22. The ER coagulation cascade Tissue Damage OTHER FACTORS V, VIII, IX, XI, XII 1.FACTOR VIIa NOVO 7 2.FACTOR Xa ==FACTOR X 3.PROTHROMBIN== THROMBIN PRADAXA FIBRONGEN ==FIBRIN CLOTS
  • 23. FEIBA  Activated Prothrombin Complex Concentrates (II, VII, IX, and X)  Dose 500U -1000U Often repeated for sustained effect up to 2000Units  Cost $1.59U/1000U = $1600/dose  Typically 1-3 doses given
  • 24. Safety Cezary et al. Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy. Int J Emerg Med 2009. Complications: 4/72 or 7% (1 peri-operative MI, 1 thrombosis of CVC, 2 NSTEMI) VERY conservative.
  • 25. FEIBA Efficacy FEIBA used in warfarin reversal: 72 patients with life-threatening bleeds on coumadin. 54% Had INR < 1.4, vs 30% of patients who received FFP. No mortality benefit, reduced hematoma expansion after ICH, rapid reversal of INR immediately (<15 minutes)
  • 26. The ER coagulation cascade Tissue Damage OTHER FACTORS V, VIII, IX, XI, XII 1.FACTOR VIIa FEIBA 2.FACTOR Xa ==FACTOR X 3.PROTHROMBIN== THROMBIN PRADAXA FIBRONGEN ==FIBRIN CLOTS
  • 27. Recommendations  Evidence is poor  Really endpoints like mortality are lacking  No good RCT comparing these options exist.  Head bleeds are bad, GI bleeds are better, and maybe reversing people doesn’t do anything at all.
  • 28. In light of good evidence 1. Pradaxa: check aPTT, if < 1.5normal = DONE - FEIBA 500U - rFVIIa 90mch/kg X 1 or about 1mg - FFP and HEMODIALYSIS (if you can find someone to dialyze them) - Activated Charcoal if within 2 hours of ingestion 2. Rivoroxaban: - PCC’s 50U/kg Profilnine - FEIBA 500-1000U 3. Warfarin - FFP 15-20cc/kg minimum of 4U - PCC’s > FFP for time to reversal (cost is similar) - We have FEIBA (cost is more but rapidly reduces reversal time)